Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Phosphatidylinositol 3-Kinases"" wg kryterium: Temat


Tytuł:
Clinical and genetic analysis of patients with segmental overgrowth features and somatic mammalian target of rapamycin (mTOR) pathway disruption: Possible novel clinical issues.
Autorzy:
Romano F; Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.
Madia F; Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
De Marco P; Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Ognibene M; Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Guerrisi S; Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Scala M; Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Iacomino M; Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Baldassari S; Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Vercellino N; Dermatology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Manunza F; Dermatology Unit, Businco Hospital, ARNAS G. Brotzu, Cagliari, Italy.
Tallone R; D.O.P.O. Ambulatory for Oncologic Follow-up, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Pavanello M; Neurosurgery Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Piatelli G; Neurosurgery Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Garaventa A; Pediatric Oncology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Zara F; Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.
Capra V; Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Pokaż więcej
Źródło:
Birth defects research [Birth Defects Res] 2022 Dec 01; Vol. 114 (20), pp. 1440-1448. Date of Electronic Publication: 2022 Nov 08.
Typ publikacji:
Case Reports; Research Support, Non-U.S. Gov't
MeSH Terms:
Phosphatidylinositol 3-Kinases*/genetics
Phosphatidylinositol 3-Kinases*/metabolism
TOR Serine-Threonine Kinases*/genetics
TOR Serine-Threonine Kinases*/metabolism
Humans ; Class I Phosphatidylinositol 3-Kinases/genetics ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Genetic Testing ; Mutation ; Syndrome
Raport
Tytuł:
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα.
Autorzy:
Hanan EJ; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Braun MG; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Heald RA; Early Discovery Charles River, 7/8 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K.
MacLeod C; Early Discovery Charles River, 7/8 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K.
Chan C; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Clausen S; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Edgar KA; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Eigenbrot C; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Elliott R; Early Discovery Charles River, 7/8 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K.
Endres N; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Friedman LS; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Gogol E; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Gu XH; Pharmaron Beijing Co., Ltd, No. 6 Taihe Road, BDA, Beijing 100176, P. R. China.
Thibodeau RH; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Jackson PS; Early Discovery Charles River, 7/8 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K.
Kiefer JR; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Knight JD; Early Discovery Charles River, 7/8 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K.
Nannini M; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Narukulla R; Early Discovery Charles River, 7/8 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K.
Pace A; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Pang J; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Purkey HE; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Salphati L; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Sampath D; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Schmidt S; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Sideris S; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Song K; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Sujatha-Bhaskar S; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Ultsch M; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Wallweber H; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Xin J; Pharmaron Beijing Co., Ltd, No. 6 Taihe Road, BDA, Beijing 100176, P. R. China.
Yeap S; Early Discovery Charles River, 7/8 Spire Green Centre, Flex Meadow, Harlow, Essex CM19 5TR, U.K.
Young A; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Zhong Y; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Staben ST; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Pokaż więcej
Źródło:
Journal of medicinal chemistry [J Med Chem] 2022 Dec 22; Vol. 65 (24), pp. 16589-16621. Date of Electronic Publication: 2022 Dec 01.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural
MeSH Terms:
Phosphatidylinositol 3-Kinases*/metabolism
Breast Neoplasms*/drug therapy
Humans ; Female ; Phosphoinositide-3 Kinase Inhibitors/pharmacology ; Phosphoinositide-3 Kinase Inhibitors/therapeutic use ; Class I Phosphatidylinositol 3-Kinases/therapeutic use ; Cell Line, Tumor ; Mutation
Czasopismo naukowe
Tytuł:
Syndromic vascular malformations related to the PIK3CA and RAS pathways: A clinical and imaging review.
Autorzy:
Tsujioka Y; Department of Radiology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan; Department of Radiology, Keio University School of Medicine, Tokyo, Japan.
Nozaki T; Department of Radiology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan; Department of Radiology, Keio University School of Medicine, Tokyo, Japan; Department of Radiology, St. Luke's International Hospital, Tokyo, Japan. Electronic address: .
Niimi Y; Department of Neuroendovascular Therapy, St. Luke's International Hospital, Tokyo, Japan.
Starkey J; Department of Diagnostic Radiology, Division of Neuroradiology, Oregon Health & Science University, Portland, OR, USA.
Hasegawa D; Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan.
Kondo M; Department of Radiology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan; Department of Radiology, St. Luke's International Hospital, Tokyo, Japan.
Enokizono M; Department of Radiology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Makidono A; Department of Radiology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Kono T; Department of Radiology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Jinzaki M; Department of Radiology, Keio University School of Medicine, Tokyo, Japan.
Pokaż więcej
Źródło:
Clinical imaging [Clin Imaging] 2022 Sep; Vol. 89, pp. 162-173. Date of Electronic Publication: 2022 Jul 02.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Phosphatidylinositol 3-Kinases*/genetics
Phosphatidylinositol 3-Kinases*/metabolism
Vascular Malformations*/diagnostic imaging
Vascular Malformations*/genetics
Class I Phosphatidylinositol 3-Kinases/genetics ; Diagnostic Imaging ; Humans ; Mutation ; Proto-Oncogene Proteins c-akt/genetics ; Proto-Oncogene Proteins c-akt/metabolism ; Quality of Life ; Signal Transduction ; Syndrome ; ras Proteins/genetics ; ras Proteins/metabolism
Czasopismo naukowe
Tytuł:
Discovery of Novel PI3Kδ Inhibitors Based on the p110δ Crystal Structure.
Autorzy:
Jia W; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmaceutical Sciences, Tianjin Medical University, Tianjin 300070, China.
Luo S; School of Stomatology, Hospital of Stomatology, Tianjin Medical University, Tianjin 300070, China.
Zhao W; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmaceutical Sciences, Tianjin Medical University, Tianjin 300070, China.
Xu W; Tianjin Institute of Pharmaceutical Research, Tianjin 300070, China.
Zhong Y; State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
Kong D; Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmaceutical Sciences, Tianjin Medical University, Tianjin 300070, China.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2022 Sep 21; Vol. 27 (19). Date of Electronic Publication: 2022 Sep 21.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/pharmacology
Phosphatidylinositol 3-Kinases*/metabolism
Adenosine Triphosphate ; Class I Phosphatidylinositol 3-Kinases ; Molecular Docking Simulation ; Protein Kinase Inhibitors/chemistry ; Protein Kinase Inhibitors/pharmacology ; Receptors, Antigen, B-Cell
Czasopismo naukowe
Tytuł:
Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP.
Autorzy:
Menteş M; Izmir University of Economics, Faculty of Engineering, Department of Genetics and Bioengineering, 35330 Balçova, İzmir, Turkey.
Karakuzulu BB; Izmir University of Economics, Faculty of Engineering, Department of Genetics and Bioengineering, 35330 Balçova, İzmir, Turkey.
Uçar GB; Izmir University of Economics, Faculty of Engineering, Department of Genetics and Bioengineering, 35330 Balçova, İzmir, Turkey.
Yandım C; Izmir University of Economics, Faculty of Engineering, Department of Genetics and Bioengineering, 35330 Balçova, İzmir, Turkey; Izmir Biomedicine and Genome Center (IBG), Dokuz Eylül University Health Campus, 35340 İnciraltı, İzmir, Turkey. Electronic address: .
Pokaż więcej
Źródło:
Computational biology and chemistry [Comput Biol Chem] 2022 Aug; Vol. 99, pp. 107726. Date of Electronic Publication: 2022 Jul 08.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/genetics
Phosphatidylinositol 3-Kinases*/chemistry
Phosphatidylinositol 3-Kinases*/genetics
Phosphatidylinositol 3-Kinases*/metabolism
Adenosine Triphosphate ; Class I Phosphatidylinositol 3-Kinases/genetics ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Female ; Humans ; Molecular Dynamics Simulation ; Mutation ; Protein Kinase Inhibitors
Czasopismo naukowe
Tytuł:
The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib.
Autorzy:
Kobialka P; Endothelial Pathobiology and Microenvironment, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
Sabata H; Endothelial Pathobiology and Microenvironment, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
Vilalta O; Endothelial Pathobiology and Microenvironment, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
Gouveia L; Endothelial Pathobiology and Microenvironment, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.; Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
Angulo-Urarte A; Endothelial Pathobiology and Microenvironment, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
Muixí L; Endothelial Pathobiology and Microenvironment, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
Zanoncello J; Endothelial Pathobiology and Microenvironment, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
Muñoz-Aznar O; Developmental Tumor Biology Laboratory, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
Olaciregui NG; Developmental Tumor Biology Laboratory, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
Fanlo L; 3D Chromatin Organization, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
Esteve-Codina A; CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain.; Universitat Pompeu Fabra (UPF), Barcelona, Spain.
Lavarino C; Developmental Tumor Biology Laboratory, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
Javierre BM; 3D Chromatin Organization, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
Celis V; Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu Barcelona, Barcelona, Spain.
Rovira C; Department of Pathology, Hospital Sant Joan de Déu Barcelona, Barcelona, Spain.
López-Fernández S; Department of Plastic Surgery, Hospital de la Santa Creu i de Sant Pau, Barcelona, Spain.
Baselga E; Department of Dermatology, Hospital Sant Joan de Déu, Barcelona, Spain.
Mora J; Developmental Tumor Biology Laboratory, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.; Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu Barcelona, Barcelona, Spain.
Castillo SD; Endothelial Pathobiology and Microenvironment, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
Graupera M; Endothelial Pathobiology and Microenvironment, Josep Carreras Leukaemia Research Institute, Barcelona, Spain.; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
Pokaż więcej
Źródło:
EMBO molecular medicine [EMBO Mol Med] 2022 Jul 07; Vol. 14 (7), pp. e15619. Date of Electronic Publication: 2022 Jun 13.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Phosphatidylinositol 3-Kinases*/genetics
Phosphatidylinositol 3-Kinases*/metabolism
Vascular Malformations*/genetics
Vascular Malformations*/metabolism
Vascular Malformations*/pathology
Aminopyridines ; Animals ; Class I Phosphatidylinositol 3-Kinases/genetics ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Endothelial Cells/metabolism ; Imidazoles ; Mice ; Mutation ; Protein Kinase Inhibitors/metabolism ; Proto-Oncogene Proteins c-akt/metabolism
Czasopismo naukowe
Tytuł:
Mutation patterns and prognostic analysis of BRAF/KRAS/PIK3CA in colorectal cancer.
Autorzy:
Wang C; Department of Gastrointestinal Surgery, Affiliated people's Hospital (Fujian Provincial People's Hospital), Fujian University of Traditional Chinese Medicine, Fujian, China.
Pan D; Department of Pathology, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fujian, China.
Pokaż więcej
Źródło:
Journal of clinical laboratory analysis [J Clin Lab Anal] 2022 Jun; Vol. 36 (6), pp. e24444. Date of Electronic Publication: 2022 Apr 18.
Typ publikacji:
Journal Article
MeSH Terms:
Class I Phosphatidylinositol 3-Kinases*/genetics
Class I Phosphatidylinositol 3-Kinases*/metabolism
Colorectal Neoplasms*/genetics
Colorectal Neoplasms*/pathology
Proto-Oncogene Proteins B-raf*/genetics
Proto-Oncogene Proteins B-raf*/metabolism
Proto-Oncogene Proteins p21(ras)*/genetics
Proto-Oncogene Proteins p21(ras)*/metabolism
Humans ; Mutation/genetics ; Phosphatidylinositol 3-Kinases/genetics ; Phosphatidylinositol 3-Kinases/metabolism ; Prognosis
Czasopismo naukowe
Tytuł:
Inhibition of lipid kinase PIKfyve reveals a role for phosphatase Inpp4b in the regulation of PI(3)P-mediated lysosome dynamics through VPS34 activity.
Autorzy:
Saffi GT; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada.
Wang CA; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada.
Mangialardi EM; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada.
Vacher J; Institut de Recherches Cliniques de Montréal (IRCM), Département de Médecine, Université de Montréal, Montréal, Québec, Canada.
Botelho RJ; Department of Chemistry and Biology, Ryerson University, Toronto, Ontario, Canada.
Salmena L; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. Electronic address: .
Pokaż więcej
Źródło:
The Journal of biological chemistry [J Biol Chem] 2022 Aug; Vol. 298 (8), pp. 102187. Date of Electronic Publication: 2022 Jun 26.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Fibroblasts*/metabolism
Phosphatidylinositol 3-Kinases*/genetics
Phosphatidylinositol 3-Kinases*/metabolism
Phosphoric Monoester Hydrolases/*metabolism
Animals ; Class III Phosphatidylinositol 3-Kinases/metabolism ; Lysosomes/metabolism ; Mice ; Phosphatidylinositol Phosphates/metabolism ; Phosphatidylinositols/metabolism ; Phosphoric Monoester Hydrolases/genetics
Czasopismo naukowe
Tytuł:
Cellular Mechanisms Underlying B Cell Abnormalities in Patients With Gain-of-Function Mutations in the PIK3CD Gene.
Autorzy:
Wang W; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Min Q; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Lai N; Key Laboratory of Whole-Period Monitoring and Precise Intervention of Digestive Cancer, Shanghai Municipal Health Commission (SMHC), Minhang Hospital, Fudan University, Shanghai, China.
Csomos K; Division of Pediatric Allergy/Immunology and Jeffrey Modell Diagnostic and Research Center, University of South Florida and Johns Hopkins All Children's Hospital, St. Petersburg, FL, United States.
Wang Y; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Liu L; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Meng X; Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Sun J; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Hou J; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Ying W; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Zhou Q; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Sun B; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Hui X; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
Ujhazi B; Division of Pediatric Allergy/Immunology and Jeffrey Modell Diagnostic and Research Center, University of South Florida and Johns Hopkins All Children's Hospital, St. Petersburg, FL, United States.
Gordon S; Division of Pediatric Allergy/Immunology and Jeffrey Modell Diagnostic and Research Center, University of South Florida and Johns Hopkins All Children's Hospital, St. Petersburg, FL, United States.
Buchbinder D; Division of Hematology, Children's Hospital of Orange Country (CHOC), Irvine, CA, United States.
Schuetz C; Department of Pediatrics, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Butte M; Division of Immunology, Allergy, and Rheumatology, Department of Pediatrics and Jeffrey Modell Diagnostic and Research Center, University of California, Los Angeles, Los Angeles, CA, United States.
Walter JE; Division of Pediatric Allergy/Immunology and Jeffrey Modell Diagnostic and Research Center, University of South Florida and Johns Hopkins All Children's Hospital, St. Petersburg, FL, United States.; Massachusetts General Hospital, Boston, MA, United States.
Wang X; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.; Shanghai Institute of Infectious Disease and Biosecurity, Shanghai, China.
Wang JY; Department of Clinical Immunology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.; Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.; Department of Microbiology and Immunology, College of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.; Division of Biochemistry, Faculty of Pharmacy and Graduate School of Pharmaceutical Science, Keio University, Tokyo, Japan.
Pokaż więcej
Źródło:
Frontiers in immunology [Front Immunol] 2022 Jun 21; Vol. 13, pp. 890073. Date of Electronic Publication: 2022 Jun 21 (Print Publication: 2022).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Gain of Function Mutation*
Phosphatidylinositol 3-Kinases*/genetics
Phosphatidylinositol 3-Kinases*/metabolism
Class I Phosphatidylinositol 3-Kinases/metabolism ; Immunoglobulin M/genetics ; Mutation
Czasopismo naukowe
Tytuł:
Reciprocal regulation of Daxx and PIK3CA promotes colorectal cancer cell growth.
Autorzy:
Huang YS; Institute of Biomedical Sciences, Academia Sinica, Taipei, 11529, Taiwan. .; The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwan. .
Wu CC; Department of Surgery, Tri-Service General Hospital Keelung Branch, National Defense Medical Center, Keelung, 20244, Taiwan.
Chang CC; The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwan.; International Ph.D. Program for Translational Science, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwan.; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, 11031, Taiwan.; Traditional Herbal Medicine Research Center, Taipei Medical University Hospital, Taipei, 11031, Taiwan.
Huang SF; Institute of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Miaoli County, 35053, Taiwan.
Kuo HY; Institute of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Miaoli County, 35053, Taiwan.
Shih HM; Institute of Biomedical Sciences, Academia Sinica, Taipei, 11529, Taiwan. .; The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwan. .; Institute of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Miaoli County, 35053, Taiwan. .
Pokaż więcej
Źródło:
Cellular and molecular life sciences : CMLS [Cell Mol Life Sci] 2022 Jun 19; Vol. 79 (7), pp. 367. Date of Electronic Publication: 2022 Jun 19.
Typ publikacji:
Journal Article
MeSH Terms:
Colorectal Neoplasms*/metabolism
Phosphatidylinositol 3-Kinases*/genetics
Phosphatidylinositol 3-Kinases*/metabolism
Cell Line, Tumor ; Cell Proliferation/genetics ; Class I Phosphatidylinositol 3-Kinases/genetics ; Co-Repressor Proteins/genetics ; Co-Repressor Proteins/metabolism ; Gene Expression Regulation, Neoplastic ; Humans ; Molecular Chaperones/genetics ; Molecular Chaperones/metabolism
Czasopismo naukowe
Tytuł:
High incidence of PI3K pathway gene mutations in South Indian cervical cancers.
Autorzy:
Rose MM; Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Chennai, Tamil Nadu 600113, India.
Dhamodharan S; Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Chennai, Tamil Nadu 600113, India.
Revathidevi S; Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Chennai, Tamil Nadu 600113, India; Human Genetics Laboratory, National Institute of Genetics, Mishima 411-8540, Japan.
Chakkarappan SR; DHR-MRU, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamil Nadu 600113, India.
Jagadeesan MG; Centre for Oncology, Royapettah Government Hospital and Kilpauk Medical College, Chennai, Tamil Nadu 600014, India.
Subbiah S; Centre for Oncology, Royapettah Government Hospital and Kilpauk Medical College, Chennai, Tamil Nadu 600014, India.
Nakaoka H; Human Genetics Laboratory, National Institute of Genetics, Mishima 411-8540, Japan; Department of Cancer Genome Research, Sasaki Institute, Sasaki Foundation, Chiyoda-ku 101-0062, Japan.
Inoue I; Human Genetics Laboratory, National Institute of Genetics, Mishima 411-8540, Japan.
Murugan AK; Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia.
Munirajan AK; Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Chennai, Tamil Nadu 600113, India; DHR-MRU, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamil Nadu 600113, India. Electronic address: .
Pokaż więcej
Źródło:
Cancer genetics [Cancer Genet] 2022 Jun; Vol. 264-265, pp. 100-108. Date of Electronic Publication: 2022 May 08.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Phosphatidylinositol 3-Kinases*/genetics
Phosphatidylinositol 3-Kinases*/metabolism
Uterine Cervical Neoplasms*/genetics
Class I Phosphatidylinositol 3-Kinases/genetics ; Female ; Human papillomavirus 16/metabolism ; Human papillomavirus 18/metabolism ; Humans ; Incidence ; Mutation/genetics ; Proto-Oncogene Proteins c-akt/genetics ; Proto-Oncogene Proteins c-akt/metabolism ; TOR Serine-Threonine Kinases/metabolism
Czasopismo naukowe
Tytuł:
Mutational landscape of pan-cancer patients with PIK3CA alterations in Chinese population.
Autorzy:
Huang Q; National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, West Huan-Hu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China.; Tianjin' S Clinical Research Center for Cancer, Tianjin, 300060, China.; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China.; Key Laboratory of Molecular Cancer Epidemiology, Tianjin, 300060, China.
Zhou Y; Genecast (Beijing) Biotechnology Co., Ltd, Beijing, 100000, China.
Wang B; Cheeloo College of Medicine, Shandong University, Jinan, 250000, China.
Zhao Y; Genecast (Beijing) Biotechnology Co., Ltd, Beijing, 100000, China.
Zhang F; Genecast (Beijing) Biotechnology Co., Ltd, Beijing, 100000, China.
Ding B; National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, West Huan-Hu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China. .; Tianjin' S Clinical Research Center for Cancer, Tianjin, 300060, China. .; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin, 300060, China. .; Key Laboratory of Molecular Cancer Epidemiology, Tianjin, 300060, China. .
Pokaż więcej
Źródło:
BMC medical genomics [BMC Med Genomics] 2022 Jul 01; Vol. 15 (1), pp. 146. Date of Electronic Publication: 2022 Jul 01.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/genetics
Phosphatidylinositol 3-Kinases*/genetics
China ; Class I Phosphatidylinositol 3-Kinases/genetics ; Female ; Humans ; Mutation ; Tumor Suppressor Protein p53/genetics
Czasopismo naukowe
Tytuł:
Cell line models for drug discovery in PIK3CA-mutated colorectal cancers.
Autorzy:
Voutsadakis IA; Algoma District Cancer Program, Sault Area Hospital, 750 Great Northern Road, Sault Sainte Marie, ON, P6B 0A8, Canada. .; Section of Internal Medicine, Division of Clinical Sciences, Northern Ontario School of Medicine, Sudbury, ON, Canada. .
Pokaż więcej
Źródło:
Medical oncology (Northwood, London, England) [Med Oncol] 2022 May 15; Vol. 39 (5), pp. 89. Date of Electronic Publication: 2022 May 15.
Typ publikacji:
Journal Article
MeSH Terms:
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Colorectal Neoplasms*/pathology
Phosphatidylinositol 3-Kinases*/genetics
Phosphatidylinositol 3-Kinases*/metabolism
Cell Line ; Class I Phosphatidylinositol 3-Kinases/genetics ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Drug Discovery ; Humans ; Microsatellite Instability ; Mutation ; Phosphoinositide-3 Kinase Inhibitors ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins p21(ras)/genetics
Czasopismo naukowe
Tytuł:
Nuclear translocation of p85β promotes tumorigenesis of PIK3CA helical domain mutant cancer.
Autorzy:
Hao Y; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 200032, Shanghai, China. .; Department of Genetics and Genome Sciences, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA. .; Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA. .
He B; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 200032, Shanghai, China.
Wu L; Department of Genetics and Genome Sciences, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.; Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.; Department of Chemistry, College of Basic Medical Sciences, Army Medical University (Third Military Medical University), Chongqing, 400038, P.R. China.
Li Y; Department of Genetics and Genome Sciences, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.; Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.
Wang C; Department of Genetics and Genome Sciences, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.; Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.
Wang T; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 200032, Shanghai, China.
Sun L; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 200032, Shanghai, China.
Zhang Y; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 200032, Shanghai, China.
Zhan Y; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, 200032, Shanghai, China.
Zhao Y; Department of Genetics and Genome Sciences, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.; Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.
Markowitz S; Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.; Department of Medicine, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.
Veigl M; Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.
Conlon RA; Department of Genetics and Genome Sciences, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.; Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA.
Wang Z; Department of Genetics and Genome Sciences, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA. .; Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH, 44106, USA. .
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2022 Apr 13; Vol. 13 (1), pp. 1974. Date of Electronic Publication: 2022 Apr 13.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Neoplasms*/drug therapy
Neoplasms*/genetics
Phosphatidylinositol 3-Kinases*/genetics
Phosphatidylinositol 3-Kinases*/metabolism
Carcinogenesis/genetics ; Class I Phosphatidylinositol 3-Kinases/genetics ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Humans ; Mutation ; Oncogenes ; Ubiquitin-Specific Peptidase 7/genetics
Czasopismo naukowe
Tytuł:
PIK3CA-related overgrowth: silver bullets from the cancer arsenal?
Autorzy:
Madsen RR; University College London (UCL) Cancer Institute, Paul O'Gorman Building, University College London, 72 Huntley Street, London WC1E 6DD, UK.
Semple RK; Centre for Cardiovascular Sciences, Queen's Medical Research Institute, University of Edinburgh, Little France Crescent, Edinburgh EH16 4TJ, UK. Electronic address: .
Pokaż więcej
Źródło:
Trends in molecular medicine [Trends Mol Med] 2022 Apr; Vol. 28 (4), pp. 255-257. Date of Electronic Publication: 2022 Mar 08.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Neoplasms*/drug therapy
Neoplasms*/genetics
Phosphatidylinositol 3-Kinases*/genetics
Phosphatidylinositol 3-Kinases*/metabolism
Class I Phosphatidylinositol 3-Kinases/genetics ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Growth Disorders/genetics ; Humans ; Mutation
Czasopismo naukowe
Tytuł:
PIK3CA hotspot mutations p. H1047R and p. H1047L sensitize breast cancer cells to thymoquinone treatment by regulating the PI3K/Akt1 pathway.
Autorzy:
Zhou J; Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Imani S; Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Shasaltaneh MD; Department of Biology, Faculty of Science, University of Zanjan, Zanjan, Iran.
Liu S; Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Lu T; Research Center for Science, Chengdu Medical College, Chengdu, Sichuan, China.
Fu J; Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, 646000, Sichuan, China. .
Pokaż więcej
Źródło:
Molecular biology reports [Mol Biol Rep] 2022 Mar; Vol. 49 (3), pp. 1799-1816. Date of Electronic Publication: 2021 Nov 23.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/genetics
Breast Neoplasms*/pathology
Phosphatidylinositol 3-Kinases*/genetics
Phosphatidylinositol 3-Kinases*/metabolism
Benzoquinones ; Class I Phosphatidylinositol 3-Kinases/genetics ; Female ; Humans ; Mutation/genetics ; Prospective Studies ; Proto-Oncogene Proteins c-akt/genetics
Czasopismo naukowe
Tytuł:
Dysregulated PI3K Signaling in B Cells of CVID Patients.
Autorzy:
Harder I; Department of Rheumatology and Clinical Immunology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; Center for Chronic Immunodeficiency (CCI), Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Münchhalfen M; Institute of Cellular and Molecular Immunology, University Medical Center Göttingen, Göttingen, Germany.
Andrieux G; Institute of Medical Bioinformatics and Systems Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Boerries M; Institute of Medical Bioinformatics and Systems Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; German Cancer Consortium (DKTK), Partner site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Grimbacher B; Institute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.; Clinic of Rheumatology and Clinical Immunology, Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.; DZIF-German Center for Infection Research, Satellite Center Freiburg, Freiburg, Germany.; CIBSS-Centre for Integrative Biological Signalling Studies, Albert-Ludwigs University, Freiburg, Germany.; RESIST-Cluster of Excellence 2155 to Hanover Medical School, Satellite Center Freiburg, Freiburg, Germany.
Eibel H; Department of Rheumatology and Clinical Immunology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; Center for Chronic Immunodeficiency (CCI), Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Maccari ME; Institute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Ehl S; Institute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.
Wienands J; Institute of Cellular and Molecular Immunology, University Medical Center Göttingen, Göttingen, Germany.
Jellusova J; Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, 81675 Munich, Germany.; TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, 81675 Munich, Germany.
Warnatz K; Department of Rheumatology and Clinical Immunology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; Center for Chronic Immunodeficiency (CCI), Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Keller B; Department of Rheumatology and Clinical Immunology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; Center for Chronic Immunodeficiency (CCI), Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Pokaż więcej
Źródło:
Cells [Cells] 2022 Jan 28; Vol. 11 (3). Date of Electronic Publication: 2022 Jan 28.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Common Variable Immunodeficiency*
Phosphatidylinositol 3-Kinases*/metabolism
B-Lymphocytes ; Class I Phosphatidylinositol 3-Kinases ; Humans ; Primary Immunodeficiency Diseases ; Signal Transduction ; TOR Serine-Threonine Kinases/metabolism
SCR Disease Name:
Activated PI3K-delta Syndrome
Czasopismo naukowe
Tytuł:
Activated phosphoinositide 3-dinase delta syndrome (APDS): An update.
Autorzy:
Lougaris V; Department of Clinical and Experimental Sciences, Pediatrics Clinic and Institute for Molecular Medicine A. Nocivelli, University of Brescia ASST-Spedali Civili di Brescia, Brescia, Italy.
Cancrini C; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.; Academic Department of Pediatrics (DPUO), Immune and Infectious Diseases Division, Research Unit of Primary Immunodeficiencies, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Rivalta B; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.; Academic Department of Pediatrics (DPUO), Immune and Infectious Diseases Division, Research Unit of Primary Immunodeficiencies, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Castagnoli R; Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.; Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Giardino G; Pediatric Section, Department of Translational Medical Sciences, Federico II University, Naples, Italy.
Volpi S; Center for Autoinflammatory Diseases and Immunodeficiency, IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genoa, Italy.
Leonardi L; Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Rome, Italy.
La Torre F; Department of Pediatrics, Giovanni XXIII Pediatric Hospital, University of Bari, Bari, Italy.
Federici S; Division of Rheumatology, IRCCS, Ospedale Pediatrico Bambino Gesù, Rome, Italy.
Corrente S; Division of Pediatrics, S. Camillo-Forlanini Hospital, Rome, Italy.
Cinicola BL; Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Soresina A; Unit of Pediatric Immunology, Pediatrics Clinic, University of Brescia, ASST-Spedali Civili Brescia, Brescia, Italy.
Marseglia GL; Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.; Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
Cardinale F; Department of Pediatrics, Giovanni XXIII Pediatric Hospital, University of Bari, Bari, Italy.
Pokaż więcej
Źródło:
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology [Pediatr Allergy Immunol] 2022 Jan; Vol. 33 Suppl 27, pp. 69-72.
Typ publikacji:
Journal Article
MeSH Terms:
Phosphatidylinositol 3-Kinases*/genetics
Primary Immunodeficiency Diseases*/diagnosis
Primary Immunodeficiency Diseases*/genetics
Class I Phosphatidylinositol 3-Kinases/genetics ; Humans ; Mutation ; Phosphatidylinositols ; Quality of Life
Czasopismo naukowe
Tytuł:
Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum.
Autorzy:
Garreta Fontelles G; Department of Pharmacy, Hospital Universitari Mutua de Terrassa, Terrassa, Spain.
Pardo Pastor J; Department of Pharmacy, Hospital Universitari Mutua de Terrassa, Terrassa, Spain.
Grande Moreillo C; Department of Pediatric Cirurgy, Hospital Universitari Mutua de Terrassa, Terrassa, Spain.
Pokaż więcej
Źródło:
British journal of clinical pharmacology [Br J Clin Pharmacol] 2022 Aug; Vol. 88 (8), pp. 3891-3895. Date of Electronic Publication: 2022 Feb 21.
Typ publikacji:
Case Reports
MeSH Terms:
Phosphatidylinositol 3-Kinase*/genetics
Phosphatidylinositol 3-Kinase*/metabolism
Class I Phosphatidylinositol 3-Kinases/*therapeutic use
Catalytic Domain ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Growth Disorders/genetics ; Humans ; Lipoma ; Musculoskeletal Abnormalities ; Mutation ; Nevus ; Phosphatidylinositol 3-Kinases ; Proto-Oncogene Proteins c-akt/genetics ; Syndrome ; Thiazoles ; Vascular Malformations
SCR Disease Name:
Congenital Lipomatous Overgrowth, Vascular Malformations, and Epidermal Nevi
Raport
Tytuł:
Lack of Functional P110δ Affects Expression of Activation Marker CD80 but Does Not Influence Functions of Neutrophils.
Autorzy:
Manda-Handzlik A; Department of Laboratory Diagnostics and Clinical Immunology of Developmental Age, Medical University of Warsaw, Zwirki i Wigury 63a Street, 02-091 Warsaw, Poland.
Mroczek A; Department of Laboratory Diagnostics and Clinical Immunology of Developmental Age, Medical University of Warsaw, Zwirki i Wigury 63a Street, 02-091 Warsaw, Poland.; Doctoral School, Medical University of Warsaw, Zwirki i Wigury 61 Street, 02-091 Warsaw, Poland.
Kuźmicka W; Department of Laboratory Diagnostics and Clinical Immunology of Developmental Age, Medical University of Warsaw, Zwirki i Wigury 63a Street, 02-091 Warsaw, Poland.
Cieloch A; Department of Laboratory Diagnostics and Clinical Immunology of Developmental Age, Medical University of Warsaw, Zwirki i Wigury 63a Street, 02-091 Warsaw, Poland.; Doctoral School, Medical University of Warsaw, Zwirki i Wigury 61 Street, 02-091 Warsaw, Poland.
Homoncik Z; Department of Laboratory Diagnostics and Clinical Immunology of Developmental Age, Medical University of Warsaw, Zwirki i Wigury 63a Street, 02-091 Warsaw, Poland.; Student's Scientific Group at Department of Laboratory Diagnostics and Clinical Immunology of Developmental Age, Medical University of Warsaw, 02-091 Warsaw, Poland.
Muchowicz A; Department of Immunology, Medical University of Warsaw, Jana Nielubowicza 5 Street, 02-097 Warsaw, Poland.; Department of Clinical Immunology, Medical University of Warsaw, Nowogrodzka 59 Street, 02-006 Warsaw, Poland.
Demkow U; Department of Laboratory Diagnostics and Clinical Immunology of Developmental Age, Medical University of Warsaw, Zwirki i Wigury 63a Street, 02-091 Warsaw, Poland.
Wachowska M; Department of Laboratory Diagnostics and Clinical Immunology of Developmental Age, Medical University of Warsaw, Zwirki i Wigury 63a Street, 02-091 Warsaw, Poland.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2022 Jun 07; Vol. 23 (12). Date of Electronic Publication: 2022 Jun 07.
Typ publikacji:
Journal Article
MeSH Terms:
Neutrophils*/metabolism
Phosphatidylinositol 3-Kinases*/metabolism
Class I Phosphatidylinositol 3-Kinases/*pharmacokinetics
Animals ; B7-1 Antigen ; Cytokines ; Follow-Up Studies ; Mice ; Spleen/metabolism
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Prześlij opinię

Twoje opinie są dla nas bardzo ważne i mogą być niezwykle pomocne w pokazaniu nam, gdzie możemy dokonać ulepszeń. Bylibyśmy bardzo wdzięczni za poświęcenie kilku chwil na wypełnienie krótkiego formularza.

Formularz